• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

AABB Revises TRALI Mitigation Requirements

October 11, 2013

The AABB’s Blood Bank/Transfusion Service Standards Program Unit has revised requirements regarding the mitigation of transfusion-related acute lung injury (TRALI). The updated requirements address an exemption previously specified in the 29th edition of Standards for Blood Banks and Transfusion Services. They will continue to require that “plasma and whole blood for allogeneic transfusion shall be from males, females who have not been pregnant, or females who have been tested since their most recent pregnancy and results interpreted as negative for HLA antibodies.” Initial requirements specified acceptable donors for “high plasma volume components,” and exempted apheresis platelets collected in platelet additive solution (PAS) from these standards. This exemption sparked concern, however, due to the residual plasma volume remaining in platelets collected in PAS still possibly causing TRALI. Consequently, platelets are no longer included in this standard.

 

Reference

1.   AABB Weekly Report. AABB Revises and Clarifies TRALI Risk Reduction Requirements. Sept 27, 2013. Accessed online: http://www.aabb.org/resources/publications/weeklyreport/Pages/default.aspx

Filed Under

  • Blood Donation
  • News
  • Quality Control and Regulatory

Recommended

  • Transfusions and Hospital IV Injections Likely Contributed to the Spread of HIV and Other Blood-borne Viruses in Africa

  • Most U.S. Patients are Likely to Find a Match for Hematopoietic Stem-Cell Transplants

  • Eculizumab Treatment May Be Beneficial For Treating Hemolysis Transfusion Reactions in Patients with Sickle Cell Disease

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Ferritin Levels Needed to Assess Hemoglobin Recovery after Blood Donation

  • Transfusion of RBCs from Cord Blood May Protect Low-Weight Preterm Infants from Severe Retinopathy

  • AABB Guidelines Recommend Liberal RBC Transfusion for Patients with Acute Myocardial Infarction

  • Artificial Intelligence to Predict Immunogenicity of Amino Acid Substitutions of Blood Group Antigens

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley